1. Academic Validation
  2. Mitochondrial transfer of drug-loaded artificial mitochondria for enhanced anti-Glioma therapy through synergistic apoptosis/ferroptosis/immunogenic cell death

Mitochondrial transfer of drug-loaded artificial mitochondria for enhanced anti-Glioma therapy through synergistic apoptosis/ferroptosis/immunogenic cell death

  • Acta Biomater. 2024 Dec 19:S1742-7061(24)00738-4. doi: 10.1016/j.actbio.2024.12.027.
Mingzhu Song 1 Jiayu Yuan 1 Ge Zhang 1 Mengdi Sun 1 Yifei Zhang 1 Xiangchen Su 1 Ruizhen Lv 1 Yuting Zhao 1 Yijie Shi 2 Liang Zhao 3
Affiliations

Affiliations

  • 1 School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, PR China.
  • 2 School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, PR China; Key Laboratory of Neurodegenerative Diseases of Liaoning Province, Jinzhou Medical University, Jinzhou, China; Collaborative Innovation Center for Age-related Disease, Jinzhou Medical University, Jinzhou, Liaoning, China. Electronic address: shiyijie119@163.com.
  • 3 School of Pharmacy, Jinzhou Medical University, Jinzhou 121000, PR China; Key Laboratory of Neurodegenerative Diseases of Liaoning Province, Jinzhou Medical University, Jinzhou, China; Collaborative Innovation Center for Age-related Disease, Jinzhou Medical University, Jinzhou, Liaoning, China. Electronic address: liangzhao79@163.com.
Abstract

Mitochondrial targeting in gliomas represents a novel therapeutic strategy with significant potential to enhance drug sensitivity by effectively killing glioma cells at the mitochondrial level. In this study, we developed artificial mitochondria derived from mitochondrial membrane-based nanovesicles, enabling precise mitochondrial targeting of doxorubicin (Dox) to selectively eradicate Cancer cells by amplifying multiple cell death pathways. It was found that Dox-encapsulating mitochondria-based nanovesicles (DOX-MitoNVs) exhibited an extraordinary ability to penetrate the blood-brain barrier (BBB), specifically targeting gliomas. By targeting mitochondria instead of locating at the nucleus, DOX-MitoNVs not only amplified Dox mediated Apoptosis effects through the overloading of intracellular CA2+ but also intensified Ferroptosis by generating Reactive Oxygen Species (ROS). Furthermore, DOX-MitoNVs demonstrated a significant ability to modulate the tumor immune microenvironment, thereby inducing pronounced immunogenic cell death (ICD) effects. In summary, it presents a novel therapeutic strategy utilizing DOX-MitoNVs for precise mitochondrial targeting in gliomas, enhancing drug sensitivity, inducing multiple cell death pathways, and modulating the tumor immune microenvironment to promote immunogenic cell death. STATEMENT OF SIGNIFICANCE: Mitochondrial targeting in gliomas is a promising therapeutic strategy that enhances drug sensitivity by exploiting glioma cells' mitochondrial vulnerabilities. We engineered mitochondrial membrane-based nanovesicles as artificial mitochondria for precise mitochondrial targeting of Dox. This approach facilitates selective Cancer cell eradication and amplifies multiple cell death pathways alongside immunogenic chemotherapy. Notably, DOX-MitoNVs effectively cross the BBB and specifically target gliomas. By focusing on mitochondria, Dox induces Apoptosis and intensifies Ferroptosis through ROS generation. Additionally, DOX-MitoNVs can transform the tumor immune microenvironment, promoting ICD. Overall, DOX-MitoNVs offer a promising platform for enhanced glioma therapy.

Keywords

Apoptosis; Doxorubicin; Ferroptosis; ICD; Mitochondria; Nanovesicles.

Figures
Products